Evidence map›Paper›PMID 42633587›Full record

ArticleThe international journal of neuropsychopharmacology2026

Chronic social defeat stress induces a hypoglycemic shift and depression-related behaviors, both prevented by antidiabetic drugs.

Wenran Qiu, Hirotaka Nagai, Kohei Ota, Midori Nagai, Tomoyuki Furuyashiki

Abstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenran QiuDivision of Pharmacology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Hirotaka NagaiDivision of Pharmacology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.ORCID 0000-0003-0983-8670
Kohei OtaDivision of Pharmacology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Midori NagaiDivision of Pharmacology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Tomoyuki FuruyashikiDivision of Pharmacology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.ORCID 0000-0001-8089-8399

Funding

AMED 25wm062-5324AMED 25zf0127010AMED 25zf0127012AMED JP24wm0425001AMED JP25wm0625-121Daiichi Sankyo Foundation of Life ScienceJapan Foundation for Applied EnzymologyJapan Society for the Promotion of Science in JapanJST Moonshot R&D JPMJMS239FKANAE foundation for the promotion of medical scienceKazato FoundationMeiji Yasuda Life Foundation of Health and WelfareMinistry of Education, Culture, Sports, Science and Technology in Japan 20K07288Ministry of Education, Culture, Sports, Science and Technology in Japan 21H04812Ministry of Education, Culture, Sports, Science and Technology in Japan 23K06358Ministry of Education, Culture, Sports, Science and Technology in Japan 24K22086SENSHIN Medical Research FoundationTakeda Medical Research FoundationTransformative Research Areas 23H04234Uehara Memorial Foundation
6 · The paper itself

Abstract

objectiveStress-related mental illnesses, including depression, are associated with altered glucose metabolism. However, it is unclear how chronic stress alters glucose metabolism along with depression-related behaviors, and how antidiabetic drugs normalize these alterations.

methodsUsing a mouse model of social defeat stress, we compared stress-induced glycemic responses among strains that differ in stress susceptibility (C57BL/6N, C57BL/6J, and BALB/c). Blood glucose was measured before stress and after the last stress exposure of acute and chronic stress. Circulating metabolic hormones and inflammatory cytokines were quantified, and depression-related behaviors (social avoidance, anhedonia-like behavior and cognitive deficits) were assessed. In C57BL/6N mice, the antidiabetic drug glyburide or liraglutide was administered 30 min before each of the 10 stress exposures, and their effects on glycemic responses and behavioral outcomes were evaluated.

resultsAcute stress elevates blood glucose in the relatively stress-resilient C57BL/6N and C57BL/6J strains, but not in the more stress-susceptible BALB/c strain. After chronic stress, this stress-induced hyperglycemic response was abolished in C57BL/6N and C57BL/6J mice, whereas BALB/c mice showed stress-induced hypoglycemia. Chronic stress also produced largely coordinated changes in circulating metabolic hormones and inflammatory cytokines, with strain-dependent differences in a subset of these molecules. In C57BL/6N mice, treatment with glyburide or liraglutide, antidiabetic drugs with distinct primary mechanisms of action, before each stress exposure reduced the development of anhedonia-like behavior and cognitive deficits without affecting social avoidance, while restoring stress-induced hyperglycemia.

conclusionsThese results demonstrate that chronic stress drives a hypoglycemic shift accompanied by depression-related behaviors, and that the development of both metabolic and behavioral alterations can be prevented by antidiabetic drugs with distinct primary mechanisms administered during the stress period. Thus, this study supports metabolically targeted interventions as a potential preventive strategy for stress-related mental illnesses, whereas their efficacy against an already established phenotype remains to be tested.

Indexed as

DepressionHypoglycemiaHypoglycemic AgentsSocial DefeatStress, PsychologicalAnhedoniaAnimalsBehavior, AnimalBlood GlucoseChronic DiseaseCytokinesDisease Models, AnimalGlyburideLiraglutideMaleMiceBlood GlucoseCytokinesGlyburideHypoglycemic AgentsLiraglutidehypoglycemiahypoglycemic agentsmicepsychologicalsocial defeatstress

Identifiers

PMID42633587
PMCPMC13557117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.